Methods for inhibiting metastasis

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C514S045000, C514S012200, C514S015800, C436S501000, C530S350000, C536S023500

Reexamination Certificate

active

06358915

ABSTRACT:

BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to methods and compositions that provide for the treatment and inhibition of metastatic carcinoma. A particular aspect of the invention relates to methods and compositions containing compounds which inhibit tumor cell proliferation and invasion, particularly those that are contain uteroglobin, uteroglobin muteins, uteroglobin mimetics, peptide analogs of uteroglobins and muteins. Further compositions of the invention include other types of active ingredients in combination with those described above.
2. Description of the Prior Art
Cancers develop from uncontrolled multiplication of cells. All cancers are life threatening. Even when cancer does not result in death, it is permanently debilitating, not only to the patient, but also to family, friends and co-workers. Too often, moreover, cancers prove fatal. The personal and public loss from this cluster of diseases, which cause a significant fraction of all premature deaths, is beyond estimation.
Although effective treatment modalities have been developed in a few cases, many cancers remain refractory to currently available therapies. Particularly difficult to treat are metastatic cancers. These cancers pose the highest risk to patients and, for optimal prognosis, often must be treated by aggressive methods that present increased risks of deleterious side-effects. Therefore, there is a great need for methods that accurately distinguish those tumors that are likely to metastasize from those that are unlikely to do so. Furthermore, methods for treating metastatic cancers often are inadequate, and there also is a clear need for improved anti-metastatic agents and methods to treat metastatic cancers.
Metastatic cancers originate from a primary tumor. Metastasis of the primary tumor produces secondary tumors and disseminated cancer. It is well known that both primary and secondary tumors shed large numbers of cells. The shed cells can spread through the body. For instance, a primary tumor may damage the surrounding lymph or circulatory vessels, allowing entry of shed cells into the lymph or circulatory systems, and hastening their spread in the body. Moreover, shedding of cells by cancerous tumors increases during surgery and radiotherapy.
Most shed cells do not form new tumors. To do so such cells must surmount a series of physical and physiological barriers. In fact, a series of distinct events must occur for metastasis to occur. The primary tumor physically must (i) invade interstitial space of the primary tissue. In particular, it must (ii) penetrate the basement membrane of the tissue. For most metastases the tumor must damage the endothelial cell wall of lymphatic or vascular vessels to provide access to shed cells. Cells that enter the lymph or blood must (iii) survive hemodynamic stress and host defenses in the circulation and, furthermore, (iv) the cells must lodge at a new site in the circulatory system, a process that apparently involves aggregated platelets. A cell then must (v) extravasate out of the vessel into the interstitial space. Finally, it must (vi) invade the interstitial space of the secondary organ and proliferate in the new location. Although the process of metastasis is physiologically complex, the overall pattern of metastasis is general to many types of cancers.
The metastatic process also clearly involves complex intracellular mechanisms that alter cancerous cells and their interactions with surrounding cells and tissues. For instance, cancerous cells are characterized by aberrant expression of adhesion proteins, enzymes that degrade matrix components, autocrine factors, ligand-responsive receptors, factors of angiogenesis and prostaglandins, to name a few. In particular, the signaling pathways that initiate tumor cell migration are among the least understood aspects of invasion and metastasis. Currently, it is thought that proliferation of many cancerous cells depends upon specific ligand-receptor interactions. Thus far, however, it has not been possible to use this paradigm, or other concepts of the underlying mechanisms of metastasis, to develop a therapy that prevents or effectively inhibits metastasis of metastatic cancers.
The complexity of the processes involved in metastasis, and the lack of understanding of underlying molecular mechanisms, have made it particularly difficult, in some cases, to distinguish tumors that are likely to metastasize from those that are unlikely to do so. The inability to discern the metastatic potential of tumors precludes accurate prognosis and leads, inevitably, to the therapeutic intervention that either is too aggressive or insufficiently aggressive. Furthermore, for all types of cancers it has been difficult or impossible, thus far, to develop treatments that inhibit or prevent the spread of metastatic tumors. Clearly, there remains a great need for methods to accurately determine the metastatic potential of tumors and for effective anti-metastatic compositions and methods.
SUMMARY OF THE INVENTION
It is therefore an object of the present invention to provide methods and compositions for inhibiting or treating metastasis.
Accordingly, the present invention relates to methods and compositions that provide for the treatment and inhibition of metastatic carcinoma. A particular aspect of the invention relates to methods and compositions containing compounds which inhibit tumor cell proliferation and invasion, particularly those that are contain uteroglobin, uteroglobin muteins, uteroglobin mimetics, peptide analogs of uteroglobins and muteins. Further compositions of the invention include other types of active ingredients in combination with those described above.
The present invention also relates to methods for gauging the metastatic potential of tumors of epithelial cell origin by determining an effector of integrin-mediated maintenance of cell invasive capacity of a tumor-containing tissue. This aspect of the invention particularly relates to determining uteroglobin protein or mRNA in cells of a biopsy sample to determine metastatic potential of a prostatic, breast, or lung tumor.
The present invention further relates to methods and compositions that treat or inhibit metastases of cancers of epithelial cell origin, especially human cancers of the prostate, breast and lung. A particular aspect of the invention relates to methods and compositions that facilitate or restore control levels of integrin-mediated maintenance of cell invasive capacity. In one aspect in this regard, the invention particularly relates to methods and compositions that replenish control levels of non-aberrant uroglobin that are diminished in patients having metastatic cancers of epithelial origin. Compositions of the invention also particularly include those that contain uteroglobin, uteroglobin muteins, and peptide analogs of uteroglobins that restore control levels of non-aberrant uteroglobin in metastatic cancer patients. Further useful in this regard are compositions that contain mimetics of uteroglobin, particularly of human uteroglobin. Further compositions of the invention include other types of active ingredients in combination with those that restore normal levels of non-aberrant uteroglobin.
The invention also particularly relates to methods to treat or inhibit metastases of human cancers of epithelial cell origin by administering the foregoing compositions. Especially in this regard the invention relates to methods using human uteroglobin to inhibit or prevent metastasis of human prostate, breast and lung cancers. Further, this aspect of the invention may be accomplished by genetic therapy.
Methods and compositions of the invention may be used by themselves and with other treatment modalities.
In accomplishing the foregoing object, there has also been provided, in accordance with one aspect of the present invention, a method for identifying an effector of integrin-mediated tumor maintenance of cell invasive capacity, comprising the step of administering to an organism suffering from a cancer of epit

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Methods for inhibiting metastasis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods for inhibiting metastasis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for inhibiting metastasis will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-2844431

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.